Surgery Partners reported a 2.4% increase in Q4 revenue to $885 million, though results were impacted by significant and unanticipated headwinds leading to a net loss of $15 million. Despite margin pressure and a decrease in total surgical cases, the company saw growth in same-facility metrics and higher-acuity procedures, while initiating a $200 million share repurchase program.

Surgery Partners delivered revenue growth of 6.6% in Q3 2025 with improved Adjusted EBITDA, but posted a net loss due to higher interest and other operating expenses.

Surgery Partners delivered a robust second quarter in 2025, with revenue increasing by 8.4% to $826.2 million and Adjusted EBITDA growing by 9.0% to $129.0 million. The company's net loss attributable to Surgery Partners, Inc. was $2.5 million. Same-facility revenues increased by 5.1%, driven by a 3.4% increase in same-facility cases and a 1.6% increase in revenue per case. The company reaffirmed its full-year 2025 revenue and Adjusted EBITDA guidance, indicating confidence in continued operational improvements and strategic growth initiatives.

In Q1 2025, Surgery Partners grew revenue and same-facility case volumes, maintained its 2025 guidance, and improved Adjusted EBITDA, despite posting a net loss due to higher interest and integration expenses.

Surgery Partners delivered strong revenue growth in Q4 2024, increasing 17.5% year-over-year. However, the company reported a net loss of $108.5 million due to a non-cash tax valuation allowance. Adjusted EBITDA grew to $163.8 million, reflecting continued operational improvements.

Surgery Partners reported a 14.3% increase in revenue to $770.4 million for the third quarter of 2024. Adjusted EBITDA was $128.6 million, representing a 21.9% increase compared to the prior year period. The company reaffirmed its full-year 2024 revenue and Adjusted EBITDA guidance.

Surgery Partners reported a 14.2% increase in revenue to $762.1 million for the second quarter of 2024, with same-facility revenues increasing by 9.9%. Adjusted EBITDA was $118.3 million, representing an 18.1% growth compared to the prior year period. The company raised its full-year guidance for revenue to greater than $3.075 billion and adjusted EBITDA to greater than $508 million.

Surgery Partners reported a 7.7% increase in revenue to $717.4 million and an Adjusted EBITDA of $97.5 million, representing an 8.2% growth compared to the prior year period. The company raised its full-year guidance to at least $3.05 billion in revenue and at least $505 million in Adjusted EBITDA.

Surgery Partners reported a 4.0% increase in revenue for the fourth quarter of 2023, reaching $735.4 million. Days adjusted same-facility revenues increased by 8.1%. The company's Adjusted EBITDA was $142.3 million, compared to $120.8 million for the same period last year.

Surgery Partners reported an 8.6% increase in revenue to $674.1 million and an adjusted EBITDA of $105.5 million, representing a 9.7% growth. Days adjusted same-facility revenues increased by 14.2%.

Surgery Partners reported revenue of $667.6 million, representing an 8.5% increase year-over-year. Net income attributable to Surgery Partners was $18.9 million, and Adjusted EBITDA was $100.2 million, a 16.4% increase. The company raised its full-year Adjusted EBITDA guidance to greater than $435 million and reaffirmed its revenue guidance at greater than $2.75 billion.

Surgery Partners, Inc. reported an 11.7% increase in revenue to $666.2 million for the first quarter of 2023. The company's net loss attributable to Surgery Partners, Inc. was $24.9 million, with an adjusted EBITDA of $90.1 million. They are raising the outlook for 2023 Adjusted EBITDA to be greater than $430 million.

Surgery Partners, Inc. announced its Q4 and full year 2022 results, with revenue increasing by 15.9% to $707.1 million for the quarter and 14.1% to $2.5 billion for the year. The company set its 2023 guidance with revenue expected to be greater than $2.75 billion and Adjusted EBITDA greater than $425 million.

Surgery Partners reported an 11.0% increase in revenue to $620.6 million, with same-facility revenues increasing 5.1%. Net loss attributable to common stockholders was $25.0 million, while Adjusted EBITDA reached $96.2 million, a nearly 26% increase from the prior year period. The company reaffirmed its projected 2022 Adjusted EBITDA of $375 million to $385 million and anticipates revenue in the range of $2.5 billion to $2.55 billion.

Surgery Partners, Inc. announced its second quarter 2022 results, with revenue increasing by 13.3% to $615.4 million and Adjusted EBITDA increasing by 13.4% to $86.1 million. The company performed over 149,000 surgical cases, a 7% increase from the prior year. They reaffirmed their 2022 Adjusted EBITDA guidance of $375 million to $385 million and revenue guidance of $2.5 billion to $2.6 billion.